In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, ...
Under terms of the deal, Gubra will receive an initial $350 million payment and could earn up to $1.875 billion more in ...
Aliya Omer, VP, US franchise head, breast cancer, AstraZeneca, discusses how results of the trial compare with other treatments for gBRCAm HER2-negative high-risk early breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback